Fundraising Fox
Remedy Plan
Rockville, US · Delaware corporation · 3 known investors
Find your way into Remedy Plan
Sign up to see every warm intro you have to Remedy Plan
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Remedy Plan team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer. Its lead clinical candidate, RPT1G, is a hyperbolic inhibitor designed to reduce NAMPT activity while avoiding the toxicity that has limited earlier attempts.
Founders & leadership
Investors · 3
How we know: 20/20 HealthCare Partners LLC's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$25.8M disclosed across 3 of 4 rounds · 2018–2025
▶$19.1MraisedAug 2023 · 22 investors · BiotechnologyRule 506(b)
- Owen HughesDirector
- Frank McCormickDirector
- Gregory CrimminsExecutive Officer, Director
- Alexandra ManickDirector
- Offering amount
- $19.6M
- Amount sold
- $19.1M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedDec 2019 · 10 investors · BiotechnologyRule 506(b)
- Frank McCormickDirector
- Alexandra ManickDirector
- Gregory CrimminsExecutive Officer, Director
- Offering amount
- $7.2M
- Amount sold
- $5.2M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedNov 2018 · 6 investors · PharmaceuticalsRule 506(b)
- Gregory Plan CrimminsExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Minimum investment
- $100K
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Remedy Plan.
In the news
Frequently asked questions
- What does Remedy Plan do?
- Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer. Its lead clinical candidate, RPT1G, is a hyperbolic inhibitor designed to reduce NAMPT activity while avoiding the toxicity that has limited earlier attempts.
- Who founded Remedy Plan?
- Remedy Plan was founded by Gregory Plan Crimmins.
- Who are Remedy Plan's investors?
- Remedy Plan's investors include 20/20 HealthCare Partners LLC, Schooner Capital, Alexandria.
- How much funding has Remedy Plan raised?
- Remedy Plan has disclosed $25.8M raised across 3 of its 4 known rounds.
- Where is Remedy Plan headquartered?
- Remedy Plan is headquartered in Rockville, US.